**Übersicht Klinische Studien:**

**Malignes Melanom (Hauttumorzentrum)**

Ansprechpartner:
Herr Prof. Dr. med. D. Schadendorf, Frau PD Dr. med. L. Zimmer, Dr. med. E. Livingstone  
Stand: 09/2018

---

**Stadium IIB/C (nicht reseziert)**

- **Firstline**
  - **BRAF**
  - **NRAS**

**Stadium III**

- **mit inoperabler Tumorlast**
- **mit symptomatischer Metastasierung**

**Stadium IV**

- **Phase II**
  - **BRAF**
  - **NRAS**

**Stadium IV**

- **mit unilateraler Metastasierung**

**Stadium IV**

- **mit operabler Tumorlast**

- **mit operabler Tumorlast und inoperablem Lymphknotenbefall**

**Stadium IV**

- **mit resezierter Tumorlast und inoperablem Lymphknotenbefall**

**Stadium IV**

- **mit resezierter Tumorlast und operablem Lymphknotenbefall**

**Stadium IV**

- **mit operabler Tumorlast und inoperablem Lymphknotenbefall**

---

**PH 19112TNF-02/15**

A pivotal Phase III, open-label, randomized, controlled multi-center study of the efficacy of 19112/L 19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B/C melanoma patients. 
Start 3. Quartal 2017

**CO39722**

A phase III, open-label, multicenter, two-arm, randomized study of investigator the efficacy and safety of Cobimetinib plus Atezolizumab versus Pembrolizumab in patients with previously untreated advanced BRAF 600 wild-type melanoma

**CA224-020**

A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

**SENSITIZE**

An open-label Phase Ib/ II, multi-center study of 4SC-202 in Combination with Pembrolizumab in Patients with Unresectable Stage III/ Metastatic Stage IV Cutaneous Melanoma primary refractory/non-responding to prior Anti-PD-1 Therapy

**CPD00112201**

A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PD15001) combinations in previously treated unresectable or metastatic melanoma.
Start Oktober 2018

**ImmuCobiVem**

A Phase II, multicenter, open-label, randomized controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti-PD-L1 antibody atezolizumab for the treatment in patients with unresectable or metastatic BRAF V600 mutant melanoma

**IMMU - TARGET**

A randomized Phase 1 / II open Label, multicenter study of encorafenib plus binimetinib and PD-1 antibody pembrolizumab in patients with unresectable or metastatic BRAF V600 mutant melanoma.
Start 3. Quartal 2017

**CA224-047**

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma

**IMCgp100-201**

A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MED14736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients with Advanced Melanoma

**CA209-184, IMMUNED**

A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma with No Evidence of Disease

**CA209-429, BRAINIP**

An open label phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and nivolumab in patients with four or more symptomatic brain metastases of melanoma